Observations placeholder
Repaglinide
Identifier
020000
Type of Spiritual Experience
Background
A description of the experience
Repaglinide is an antidiabetic drug in the class of medications known as meglitinides, and was invented in 1983. Repaglinide is an oral medication used in addition to diet and exercise for blood sugar control in type 2 diabetes mellitus The mechanism of action of Repaglinide involves promoting insulin release from β-islet cells of the pancreas; like other antidiabetic drugs, a main side effect concern is hypoglycemia. Trade names include Prandin in the U.S., GlucoNorm in Canada, Surepost in Japan, Repaglinide in Egypt by EIPICO, and NovoNorm elsewhere.
Adverse events
Common adverse events include:
Metabolic
- Hypoglycemia (31%)
Respiratory
- Upper respiratory infection (16%)
- Sinusitis (6%)
- Rhinitis (3%)
Gastrointestinal
- Nausea (5%)
- Diarrhea (5%)
- Constipation (3%)
- Vomiting (3%)
Musculoskeletal
- Arthralgia (6%)
- Back Pain (5%)
Other
- Headache (11%)
- Paresthesia (3%)
Serious adverse events include:
- Cardiac ischemia (2%)
- Angina (1.8%)
- Deaths due to cardiovascular events (0.5%)
On Jan, 09, 2017 2,696 people reported to have side effects when taking Repaglinide.
Among them, 19 people (0.7%) have Hallucination
On Feb, 7, 2016: 1,814 people reported to have side effects when taking Repaglinide. Among them, 38 people (2.09%) have Death.
Time on Repaglinide when people have Death :
< 1 month | 1 - 6 months | 6 - 12 months | 1 - 2 years | 2 - 5 years | 5 - 10 years | 10+ years | |
Death | 40.00% | 0.00% | 0.00% | 40.00% | 0.00% | 20.00% | 0.00% |